UBXN2A Antibody

Code CSB-PA225237
Size US$166
Order now
Image
  • Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: CSB-PA225237(UBXN2A Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
UBXN2A
Alternative Names
UBXN2A antibody; UBXD4 antibody; UBX domain-containing protein 2A antibody; UBX domain-containing protein 4 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Synthetic peptide of Human UBXN2A
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,WB
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
WB 1:200-1:1000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*